{
    "nct_id": "NCT03184038",
    "official_title": "Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study",
    "inclusion_criteria": "* Pathologically proven solid tumor malignancy (except for small cell lung cancer [SCLC], germ cell tumor)\n* Karnofsky performance status >= 60\n* 1 to 10 brain metastases (mets) (no more than two lesions and/or cavities >= 3 cm in maximum diameter)\n* Maximum diameter of brain metastasis or resection cavity is 6 cm\n* Serum creatinine =< 3 mg/dL and creatinine clearance >= 30 ml/min\n* Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up; patients must be willing to complete neurocognitive assessments at pre-specified time points outlined in the protocol\n* Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 21 days prior to registration\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose\n* Patient able to provide his/her own written informed consent and speak English\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor\n* Prior brain surgery =< 14 days prior to enrollment\n* Planned chemotherapy during radiosurgery\n* Leptomeningeal metastases\n* Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per week for the past 2 months\n* Pregnant women",
    "miscellaneous_criteria": ""
}